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compared to calcitonin and alendronate. Furthermore,
hazard ratios showed that patients taking ERT, ralox-
ifene, or alendronate were approximately 83% less likely
to experience fracture at any point in time compared to
calcitonin.
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BACKGROUND: The UK has more than 19 million peo-
ple aged over 50, including about 9.4 million aged over
65. Demographic changes will lead to increases in the
over-50 population of 10% and 25% by 2010 and 2020,
respectively. There are already 3 million UK residents
with osteoporosis, but the prevalence of osteoporosis in-
creases with age, and the public health impact of os-
teoporosis will increase substantially over the next 20
years. OBJECTIVE: To predict fracture numbers and
corresponding costs for men and women aged 50–99
years in the UK for the years 2000 to 2020. METHODS:
A Markov model was designed to simulate the natural
history of osteoporosis within the UK population. Inputs
to the model included age/sex specific fracture incidence
rates, published unit costs for different fracture types
(hip, vertebral, forearm/wrist, other), age/sex specific
mortality rates, and age/sex specific population totals.
Total fracture numbers were adjusted using published
site-specific attribution figures to identify the number
that were a consequence of osteoporosis. Iteration tech-
niques were employed across ages 50–99 in men and
women, to generate the distribution of prevalence-based
estimates of fractures and costs for the base year 2000.
Osteoporosis costs and fracture numbers were then pro-
jected into future years by applying growth rates in age/
sex specific population totals to these year 2000 esti-
mates. RESULTS: In 2000 there were 190,000 os-
teoporosis-related fractures at a cost of £1.8 billion. Men
accounted for 32,000 fractures and £330 million. By
2020, annual osteoporotic fracture numbers increased by
over 21% to 230,000, with costs growing by 20% to
over £2.1 billion. Cumulative totals for 2000–2010 were
2.2 million fractures and £20.3 billion. CONCLUSIONS:
Osteoporotic fractures will have substantial and increas-
ing impacts on UK health services unless highly effective
preventative interventions achieve widespread use.
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OBJECTIVE: While Cox 2 inhibitors have a theoretical
advantage over other nonsteroidal anti-inflammatory
drugs (NSAIDS) by reducing gastrointestinal (GI) side ef-
fects, not all individuals are at increased risk of GI com-
plications and therefore may benefit equally from non-
Cox 2 specific NSAIDS. This study determined the use of
Cox 2 inhibitors by subjects with no identifiable GI risk.
The cost of this “inappropriate use” was estimated.
METHODS: This was a longitudinal claims data analysis
using 1999 medical, pharmacy and enrollment data from
a large national health plan. Subjects were identified as
either Cox 2 users (n  23,190) or other NSAID users
(n  192,079) from pharmacy claims, and total NSAID
costs were calculated for a six-month period. RESULTS:
Cox 2 users were more likely to have a GI risk factor,
(prior GI events, age over 60 years, chronic NSAID use of
two or more prescriptions in the six months prior to the
first Cox 2 claim, and prior corticosteroid use) compared
to other NSAID users. Because individuals with arthritis
may require on-going NSAID use, a diagnosis of arthritis
(OA or RA) was also considered a risk factor for GI com-
plications. Having an arthritis diagnosis was more likely
among Cox 2 users compared to other NSAID users
(44.1% and 13.0% respectively). Twenty-six percent of
Cox 2 users had neither a discernable GI risk nor an ar-
thritis diagnosis. An unadjusted cost comparison between
Cox 2 subjects with no GI risk and no arthritis and simi-
lar other NSAID subjects found a significant mean differ-
ence of $131 per person in NSAID costs for six months.
CONCLUSIONS: Despite health plan policies to manage
the use of Cox 2 inhibitors, a quarter of Cox 2 users ap-
peared to be inappropriate. The total health system cost
of this potentially inappropriate use was $775,000 for six
months.
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OBJECTIVES: Quality of life is a key parameter in de-
scribing the health status patients of rheumatoid arthritis.
Construct validity of a generic (EQ-5D) and a disease
specific (RAQoL) quality of life instrument was tested
with the intention of further use in clinical and health
economic trials and burden of disease studies in Hun-
gary. METHODS: RAQoL and EQ-5D have been re-
cently adapted into Hungarian. Authors analysed the de-
mographic and QoL data from a cross-sectional postal
survey of patient with rheumatoid arthritis. The conver-
gent validity of EQ-5D, RAQoL scores has been com-
pared to functional measurement scores from the Health
Assessment Questioner (HAQ). Pearson correlation coef-
